Epigenetics Drugs & Diagnostic Technologies Market, by Type (Epigenetic Drugs, (DNMT Inhibitors (Azacitidine and Decitabine), HDAC Inhibitors (Vorinostat, and Romidepsin) and Others) and Epigenetics Diagnostic Technologies (DNAMethylation and CHIP Technol
Description
Epigenetics Drugs & Diagnostic Technologies Market, by Type (Epigenetic Drugs, (DNMT Inhibitors (Azacitidine and Decitabine), HDAC Inhibitors (Vorinostat, and Romidepsin) and Others) and Epigenetics Diagnostic Technologies (DNAMethylation and CHIP Technology) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Epigenetics is the study of chemical modifications of some specific genes of an organism. Epigenetic drugs are used to reverse the abnormal gene expression which leads to different types of diseases such as cancer, heart disease, diabetes, and mental illnesses. Increasing prevalence of cancer, increasing research and development for new drug molecule along with increasing investment in biotechnology industry is expected to propel market growth during the forecasted period.
Market Dynamics
Increasing prevalence of cancer is expected to drive the market growth during the forecast period.
According to the World Health Organization, cancer is a leading cause of death worldwide, which accounted for around 10 million deaths in 2020. The most common cancer, in terms of new cases of cancer were breast (2.26 million cases), lung (2.21 million cases) and colon & rectum (1.93 million cases).
Epigenetic changes are commonly associated with all human cancers and often responsible for genetic alterations driving the cancer phenotype. The changes includes histone modifiers and readers, Deoxyribonucleic acid (DNA) methylation, chromatin remodelers, and other components of chromatin. The epigenetic changes can lead to mutations in genes which eventually causes modification of the epigenome.
The function of epigenetic drugs in that they help in reversing these epigenetic changes. Epigenetic therapies are often used in the treatment of solid tumors and other types of cancer.
Key features of the study:
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Others
CHIP Technology
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Epigenetics is the study of chemical modifications of some specific genes of an organism. Epigenetic drugs are used to reverse the abnormal gene expression which leads to different types of diseases such as cancer, heart disease, diabetes, and mental illnesses. Increasing prevalence of cancer, increasing research and development for new drug molecule along with increasing investment in biotechnology industry is expected to propel market growth during the forecasted period.
Market Dynamics
Increasing prevalence of cancer is expected to drive the market growth during the forecast period.
According to the World Health Organization, cancer is a leading cause of death worldwide, which accounted for around 10 million deaths in 2020. The most common cancer, in terms of new cases of cancer were breast (2.26 million cases), lung (2.21 million cases) and colon & rectum (1.93 million cases).
Epigenetic changes are commonly associated with all human cancers and often responsible for genetic alterations driving the cancer phenotype. The changes includes histone modifiers and readers, Deoxyribonucleic acid (DNA) methylation, chromatin remodelers, and other components of chromatin. The epigenetic changes can lead to mutations in genes which eventually causes modification of the epigenome.
The function of epigenetic drugs in that they help in reversing these epigenetic changes. Epigenetic therapies are often used in the treatment of solid tumors and other types of cancer.
Key features of the study:
- This report provides an in-depth analysis of the global epigenetics drugs & diagnostic technologies market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global epigenetics drugs & diagnostic technologies market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Regenacy Pharmaceuticals, Inc., Astex Pharmaceuticals, 4SC AG, CellCentric Ltd., Celleron Therapeutics Ltd., Bristol-Myers Squibb Company, Oryzon Genomics S.A., ChromaMedicine, Inc., Epizyme, Inc., and EpiGentek Group Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global epigenetics drugs & diagnostic technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epigenetics drugs & diagnostic technologies market
- Global Epigenetics Drugs & Diagnostic Technologies Market, By Type:
- Epigenetic Drugs
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Others
- Epigenetics Diagnostic Technologies
CHIP Technology
- Global Epigenetics Drugs & Diagnostic Technologies Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Regenacy Pharmaceuticals, Inc.*
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
- Astex Pharmaceuticals
- 4SC AG
- CellCentric Ltd.
- Celleron Therapeutics Ltd.
- Bristol-Myers Squibb Company
- Oryzon Genomics S.A.
- ChromaMedicine, Inc.
- Epizyme, Inc.
- EpiGentek Group Inc.
Table of Contents
149 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Type
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Key Highlights
- Product Launch/Approvals
- PEST Analysis
- Technological Advancements
- Regulatory Scenario
- Mergers, Acquisitions and Collaborations
- 4. Global Epigenetic Drugs & Diagnostic Technologies Market – Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand of Epigenetics Drugs & Diagnostic Products
- 5. Global Epigenetic Drugs & Diagnostic Technologies Market, By Type, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Epigenetic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- DNMT Inhibitors
- Azacitidine
- Decitabine
- HDAC Inhibitors
- Vorinostat
- Romidepsin
- Others
- Epigenetics Diagnostic Technologies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- DNAMethylation
- CHIP Technology
- 6. Global Epigenetic Drugs & Diagnostic Technologies Market, By Region, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2030
- North America
- Market Size and Forecast, By Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Region/Country, 2017 – 2030, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- 7. Competitive Landscape
- Competitive Snapshot
- Regenacy Pharmaceuticals, Inc.*
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Astex Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- 4SC AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- CellCentric Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Celleron Therapeutics Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Oryzon Genomics S.A.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- ChromaMedicine, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Epizyme, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- EpiGentek Group Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- 8. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 20 market data tables and 21 figures on "Epigenetic Drugs & Diagnostic Technologies Market” - Global forecast to 2030
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
